XML 23 R7.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Conversion Of Class B Common Stock To Class A Common Stock
Common Class A
Common Class B
Common Stock
Common Class A
Common Stock
Common Class A
RSUs
Common Stock
Common Class A
RSAs
Common Stock
Common Class A
Conversion Of Class B Common Stock To Class A Common Stock
Common Stock
Common Class B
Common Stock
Common Class B
Conversion Of Class B Common Stock To Class A Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2019           60,955,000       33,863,000          
Beginning balance at Dec. 31, 2019 $ 257,652 $ (252)       $ 1       $ 1   $ 449,463 $ 196 $ (192,009) $ (252)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Issuance of Class A common stock issued in connection with the follow-on public offering, net of underwriting discounts (in shares)           6,900,000                  
Issuance of Class A common stock issued in connection with the follow-on public offering, net of underwriting discounts 274,177                     274,177      
Shares issued related to a business combination (in shares)           6,368,000                  
Shares issued related to a business combination 622,595                     622,595      
Value of equity awards assumed in a business combination 1,129                     1,129      
Restriction of stock awards (in shares)           (896,000)                  
Restriction of stock awards $ (87,714)                     (87,714)      
Vesting of restricted stock awards (in shares) 112,000                            
Exercise of stock options (in shares)           4,360,000                  
Exercise of stock options $ 15,273                     15,273      
Exercise of common stock warrants (in shares)                   145,000          
Vesting of early exercised stock options (in shares)                   109,000          
Vesting of early exercised stock options 467                     467      
Vesting of restricted stock (in shares)           1,377,000                  
Issuance of common stock under (ESPP in shares)           331,000                  
Shares issued under ESPP 8,193                     8,193      
Stock-based compensation 66,467                     66,467      
Conversion of Class B to Class A Stock (in shares)           23,888,000       (23,888,000)          
Net loss (95,932)                         (95,932)  
Other comprehensive loss (190)                       (190)    
Ending balance (in shares) at Dec. 31, 2020           103,394,000       10,229,000          
Ending balance at Dec. 31, 2020 1,061,865         $ 1       $ 1   1,350,050 6 (288,193)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Exercise of stock options (in shares)           2,188,000                  
Exercise of stock options 12,626                     12,626      
Vesting of early exercised stock options (in shares)           48,000       43,000          
Vesting of early exercised stock options 405                     405      
Vesting of restricted stock (in shares)             2,000,000 448,000              
Proceeds from sale of restricted shares (in shares)           224,000                  
Proceeds from sale of restricted shares 10,655                     10,655      
Issuance of common stock under (ESPP in shares)           236,000                  
Shares issued under ESPP 8,798                     8,798      
Stock-based compensation 144,934                     144,934      
Conversion of Class B to Class A Stock (in shares)                 10,272,000   (10,272,000)        
Conversion of Class B to Class A Stock     $ 0           $ 1   $ (1)        
Net loss (222,697)                         (222,697)  
Other comprehensive loss $ (2,633)                       (2,633)    
Ending balance (in shares) at Dec. 31, 2021 118,810,611     118,800,000   118,811,000       0          
Ending balance at Dec. 31, 2021 $ 1,013,953         $ 2       $ 0   1,527,468 (2,627) (510,890)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                              
Exercise of stock options (in shares) 1,778,000         1,778,000                  
Exercise of stock options $ 5,688                     5,688      
Vesting of restricted stock (in shares)             3,119,000 112,000              
Issuance of common stock under (ESPP in shares)           516,000                  
Shares issued under ESPP 4,665                     4,665      
Stock-based compensation 128,285                     128,285      
Net loss (190,774)                         (190,774)  
Other comprehensive loss $ (6,659)                       (6,659)    
Ending balance (in shares) at Dec. 31, 2022 124,336,171     124,300,000 0 124,336,000       0          
Ending balance at Dec. 31, 2022 $ 955,158         $ 2       $ 0   $ 1,666,106 $ (9,286) $ (701,664)